CHROMBIO. 6181

Enzymic preparation of dioxygen-18 labelled leukotriene E_4 and its use in quantitative gas chromatography-mass spectrometry

Dimitrios Tsikas*, Joachim Fauler and Jürgen C. Frölich

Department of Clinical Pharmacology, Hannover Medical School, Konstanty-Gutschow-Strasse 8, W-3000 Hannover 61 (Germany)

(First received August 7th, I991; revised manuscript received October 14th, 1991)

ABSTRACT

A simple and rapid method is described for the preparation of a stable isotope oxygen-18 labelled leukotriene E_a (LTE_a). Oxygen-18 labelling of LTE₄ methyl ester in oxygen-18 water catalysed by a pig liver esterase resulted in the incorporation of two oxygen-18 atoms in the carboxylic group of LTE₄ to the extent of 89.8% ($[^{18}O_2]$ LTE₄) and one oxygen-18 atom to the extent of 9.4% ($[^{16}O^{18}O]$ LTE₄), with only 0.7% remaining unchanged ($[^{16}O_2]LTE_4$). $[^{18}O_2]LTE_4$ was found not to back-exchange following incubation in acidified urine (pH 4.0) at 4°C for up to 20 h. $[18O_2]LTE_4$ was demonstrated to be a useful internal standard in a method for the quantitative determination of LTE, in human urine involving high-performance liquid chromatography and gas chromatography with negative-ion chemical ionization tandem mass spectrometry: the concentration of $LTE₄$ in a 24-h urine sample of a healthy subject was determined to be 68.1 pg/ml.

INTRODUCTION

Leukotriene E_4 (LTE₄) is the major urinary metabolite in humans of $LTC₄[1–3]$, which is one of the most potent lipid mediators of anaphylaxis and inflammation [4]. Quantitative determination of urinary LTE4 was found to be useful to study the rate of synthesis of cysteinyl leukotrienes in human health and diseases [5-71. Commonly, quantitation of LTE₄ is performed by radioimmunoassay [8,9] or enzyme-linked immunoassay [IO] after its separation by reversedphase high-performance liquid chromatography (RP-HPLC). Gas chromatography-mass spectrometry (GC-MS), which is widely used for the quantitation of eicosanoids in biological fluids, has recently been reported to be suitable for the analysis of LTC_4 , LTD_4 , and LTE_4 [11]. This method is based on the catalytic conversion of these compounds into 5-hydroxyeicosanoic acid (S-HEA), which can be sensitively analysed by GC-MS. Accurate and selective quantitation of LTE_4 in urine by this method requires, however, a stable isotope-labelled LTE_4 analogue as internal standard, and separation of $LTE₄$ by RP-HPLC from other cysteinyl leukotrienes and 5 hydroxyeicosatetraenoic acid (5-HETE) because these are also converted to 5-HEA. The use of deuterated LTE₄ analogues seems to be unsuitable because, during catalytic hydrogenation, exchange of deuterium with hydrogen occurs in these compounds [11]. On the other hand, ^{18}O labelled 5-HETE as internal standard for LTE₄ [l I] is suitable only for semi-quantitative determination, because its HPLC behaviour is different from that of LTE₄.

This paper describes the enzymic preparation of $[^{18}O_2]$ LTE₄ from LTE₄ methyl ester, using a commercially available pig liver esterase according to standard methods for the labelling of eicosanoids [12-14]. The usefulness of this stable isotope-labelled LTE_4 analogue in the quantitative GC – MS determination of $LTE₄$ in human urine is also demonstrated.

EXPERIMENTAL

Chemicals and reagents

 LTE_4 free acid, LTE_4 methyl ester and N,Ndiisopropylethylamine were purchased from Sigma (Munich, Germany). $[14,15-3H(N)]LTE_4$ was obtained from DuPont (Dreieich, Germany). Pig liver esterase (PLE, 130 units/mg) was from Boehringer Mannheim (Mannheim, Germany). $H₂¹⁸O$ (97.8 atom% oxygen-18) was obtained from MSD Isotopes Merck Frosst Canada (Montreal, Canada). Li¹⁸OH (0.36 *M*) was prepared by dissolving the appropiate amount of lithium in H_2 ¹⁸O. The catalyst used for reduction of LTE₄ was 5% (w/w) Rh on Al_2O_3 and purchased from Fluka (Neu Ulm, Germany). Pentafluorobenzyl (PFB) bromide was obtained from Aldrich (Steinheim, Germany) and N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) was from Pierce (Rockford, IL, USA). Acetonitrile and methanol of gradient grade were purchased from Merck (Darmstadt, Germany).

Solid-phase extraction and reversed-phase HPLC

Solid-phase extraction on 300-mg Sep-Pak C_{18} cartridges from Waters and RP-HPLC of enzyme incubation mixtures and urine samples were performed as described previously [7]. Gradient elution at a flow-rate of 1.0 ml/min was used. The effluent was monitored at 280 nm. Quantitation of enzymically synthesized $[^{18}O_2]$ LTE₄ was performed by RP-HPLC using appropiate amounts of synthetic LTE_4 and a molar absorptivity (a) of 40 000. Identical retention times for synthetic LTE₄ and $[^{18}O_2]$ LTE₄ were found (45.55 min).

Enzymic preparation of $I^{18}O_2/LTE_4$

LTE₄ methyl ester (25 μ g in 65% aqueous methanolic potassium phosphate buffer, pH 7.0) and PLE (195 units in ammonium sulphate suspension) were dried under vacuum. The PLE residue was disolved in 90 μ l of H₂¹⁸O, and this suspension was used for dissolving the residue of the LTE4 methyl ester solution. The pH was adjusted to 7.5 by treating the resulting suspension with 5 μ 1 of 0.36 M Li¹⁸OH. The mixture was incubated at 37°C for 16 h. The reaction was stopped by addition of 500 μ l of ice-cold ethanol, and the mixture was allowed to stand at -20° C

for 30 min. Thereafter, the mixture was diluted with 1 ml of water and centrifuged (2000 g , 5 min). Aliquots of 100 μ l were injected into the RP-HPLC system, and the peaks with the retention time of synthetic LTE_4 were collected. LTE_4 was recovered by solid-phase extraction and stored in methanol-water (1:1, v/v) at -80° C.

Catalytic reduction and derivatization

LTE₄ and ¹⁸O-labelled LTE₄ were converted into the corresponding 5-HEAs by catalytic reduction and desulphurization, using 5% (w/w) $Rh/Al₂O₃$ and hydrogen gas by the modified method of Balazy and Murphy [11]. Briefly, 5 mg of the catalyst were suspended in a methanolic solution of $LTE₄$, the suspension was gently shaken and allowed to stand for 5 min on ice, and hydrogen gas was bubbled through the suspension for 20 min at 0°C. Thereafter the sample was centrifuged (2000 g, 5 min), methanol was taken up, the catalyst washed with 1 ml of methanol and the suspension centrifuged again. The combined methanol supernatants were evaporated under a stream of nitrogen, the residue was reconstituted in 1 ml of water and extracted twice with 1 ml of ethyl acetate, and the solvent was dried over sodium sulphate and then removed under nitrogen. 5-HEAs obtained from this process were converted by standard derivatization procedures into their PFB ester trimethylsilyl (TMS) ether derivatives using PFB bromide followed by BSTFA.

Gas chromatography-mass spectrometry

GC-MS and GC-MS-MS were performed on a Finnigan 9611 gas chromatograph equipped with a fused-silica capillary column OV-I (25 m \times 0.25 mm I.D., 0.25 μ m film thickness) from Macherey-Nagel (Diiren, Germany) connected to a Finnigan MAT TSQ 45 mass spectrometer (San Jose, CA, USA). The injector was kept at 28O"C, and the column held at 100°C for 2 min, then programmed to 320°C at 25"C/min. The column led directly into the ion source which was kept at 120°C. Helium was used as a carrier gas at a pressure of 55 kPa. A constant temperature of 240°C was kept at the interface. Methane was used as reagent gas for negative-ion chemical ionization (NICI) at a pressure of 65 Pa. The ionization energy was 90 eV for NICI and 70 eV for electron impact (EI) at an electron current of 300 μ A. In GC-MS-MS experiments, argon was used for collision-activated dissociation (CAD) at a collision cell pressure at 3 mTorr. The collision energy was set at 20 eV. The electron multiplier voltage was 2000 V.

RESULTS AND DISCUSSION

The EI mass spectrum of the PFB-TMS derivative of $18O$ -labelled LTE₄ is shown in Fig. 1. The ion at m/z 313 results from fragmentation between carbon atoms 4 and 5 $(C_{16}H_{32}$ -OTMS)+, and was also observed from unlabelled LTE4. In contrast, the ion at *m/z* 373 was observed only from 18 O-labelled LTE₄ and results from fragmentation between carbon atoms 5 and 6 $(C_5H_7 - TMSO - {}^{18}O_2PFB)^+$, and is increased by four atom mass units (a.m.u.) with respect to the corresponding ion $(m/z 369)$ of unlabelled LTE4. The EI mass spectrum of enzymically 18 O-labelled LTE₄ clearly indicates that this compound is $[1,1^{-18}O_2]$ 5-hydroxyeicosanoic acid, which is formed from enzymically produced $[1, 1^{-18}O_2]$ LTE₄ by catalytic reduction and desulphurization.

In Fig. 2 the NICI mass spectrum of enzymically 18 O-labelled LTE₄ is shown. The most intense ions are m/z 403 (M – PFB)⁻ and m/z 313 $(M - PFB - TMSOH)^{-}$. They are increased by four a.m.u. with respect to unlabelled LTE₄ (m/z) 399 and 309, respectively). These findings indicate that two 18 O atoms were incorporated in the molecule of LTE₄. Furthermore, the NICI mass spectrum of 18 O-labelled LTE₄ shows a significantly less intensive signal at *m/z* 401 (incorporation of one ¹⁸O atom) and no signal at m/z 399 (no incorporation of 180 atoms). The extent of the incorporation of ^{18}O atoms into LTE₄ was determined by NICI selected-ion monitoring (SIM) on *m/z* 403, *m/z* 401 and *m/z* 399. Fig. 3 shows a partial GC-MS chromatogram from the NICI-SIM analysis at these ions of enzymically prepared $[$ ¹⁸O₂]LTE₄ after RP-HPLC separation. Integration of the area of the peaks with scan number 2792 gave 89.8% [¹⁸O₂]LTE₄, 9.4% $[16O^{18}O]$ LTE₄ and 0.7% unlabelled LTE₄. The total yield of $[^{18}O_2]$ LTE₄ was determined to be 16% (4 μ g) by HPLC and UV detection (280 nm, $a = 40 000$.

The applicability of $[^{18}O_2]LTE_4$ as an internal standard was checked by catalytic hydrogenation of various amounts of LTE_4 (zero to 10 ng) each

Fig. 1. EI mass spectrum of the PFB ester TMS ether derivative of $[1,1^{-18}O_2]5$ -HEA obtained from enzymically prepared $[^{18}O_2]LTE_4$ after HPLC analysis, catalytic reduction and desulphurization.

Fig. 2. NICI mass spectrum from the PFB ester TMS ether derivative of enzymically prepared [¹⁸O₂]LTE₄ after HPLC analysis. catalytic reduction and desulphurization.

spiked with 0.55 ng of $[^{18}O_2]$ LTE₄. Linear regression of the ratio m/z 399 to 403 (y) on the amount of $LTE_4(x)$ gave a straight line, with the regression equation $y = 0.084 + 1.678x$ (r > 0.985).

The usefulness of $[^{18}O_2] \text{LTE}_4$ as an internal standard in the quantitative determination of $LTE₄$ in human urine by GC-MS-MS was investigated by analysis of 20-ml urine samples spiked with $[^{18}O_2]$ LTE₄ and $[^{3}H]$ LTE₄ as described in Experimental and in ref. 7. Fig. 4 shows a partial NICI GC-MS-MS chromatogram from a human urine sample spiked with 3 ng of $\binom{18}{2}$ LTE₄ obtained by SIM at *m*/z 253. This ion was also observed from CAD of the parent ions $(M - PFB)^{-}$ on m/z 399 (LTE₄) and m/z 403 ($\binom{18}{2}$ LTE₄) (Fig. 5). As CAD of the parent ions $(M - PFB)^{-}$ of the deuterated internal standards $[20,20,20^{-2}H_3]LTE_4$ and $[14,15,17,17,18,18^{-2}H_6]$ LTE₄ leads to the forma-

Fig. 3. Partial GC-MS chromatogram obtained from enzymically prepared $[^{18}O_2] \text{LTE}_4$ by SIM on m/z 403 $([^{18}O_2] \text{LTE}_4)$, m/z 401 $($ [¹⁶O¹⁸O]LTE₄) and *m*/z 399 ([¹⁶O₂]LTE₄).

Fig. 4. Partial GC-MS-MS chromatogram from the analysis of a human urine sample (20 ml) spiked with 3 ng of $[^{18}O_2]$ LTE₄. SIM on m/z 253, the same daughter ion of endogenous LTE₄ and $[{}^{18}O_2]$ LTE₄ (see also Fig. 5). The concentration of endogenous LTE₄ in this urine sample was 68.1 pg/ml.

tion of daughter ions with m/z 256 and m/z 259 respectively, due to the number of deuterium atoms, these daughter ions of LTE₄s probably result from loss of a moiety containing both oxygen atoms of the carboxylic group [15]. The 5- HEA derivatives of endogenous $LTE₄$ as well as $[^{18}O_2]$ LTE₄ emerged from the column at the same time. The concentration of endogenous $LTE₄$ in this urine sample was determined to be 68.1 pg/ml.

Back-exchange of ^{18}O with ^{16}O in ^{18}O -labelled eicosanoids is a common phenomenon, which mainly depends on esterase activities in biological materials and the ability of eicosanoids to form lactones [14]. Under the conditions used in our method for solid-phase extraction of LTE4 from urine and HPLC separation [7], and catalytic reduction and desulphurization as described, no back-exchange was observed following separate incubation of 3 ng of $\binom{18}{2}$ LTE₄ in 20 ml of acidified urine (pH 4.0) at 4°C for 30 min and 20 h. The ratios of the peak areas of $[{}^{16}O_2]$ LTE₄ to $[{}^{18}O_2]$ LTE₄ were determined to be 0.454 and 0.481, respectively. This difference lies within the variance of the reproducibility of the method. Also, $[^{18}O_2] \text{LTE}_4$ may be useful for GC –MS quantitation of LTE_4 in other biological

materials when esterase-catalysed back-exchange is avoided by enzyme denaturation, as has been previously reported for other '*O-labelled eicosanoids [12-141.

The use of pig liver esterases and H_2 ¹⁸O to introduce 18 O atoms into the carboylic group of $LTE₄$ methyl esters is an elegant method to prepare rapidly and easily $[^{18}O_2]LTE_4$ under mild conditions with sufficient yield. $[^{18}O_2]LTE_4$ is stable in urine for several hours and during catalytic hydrogenation/desulphurization, has the same retention time on RP-HPLC as endogenous LTE4, and is therefore a useful internal standard in the quantitative determination of endogenous LTE₄ in human urine by GC-MS. Other ^{18}O labelled cysteinyl leukotrienes could be prepared by this method and used as internal standards in GC-MS quantitation of their endogenous analogues.

ACKNOWLEDGEMENTS

This work was supported by grants from the Deutsche Forschungsgemeinschaft Fr 366/5-2 and Bundesministerium fiir Forschung und Technologie 01VM90020.

Fig. 5. Daughter mass spectra of unlabelled LTE₄ (a) and $[{}^{18}O_2]$ LTE₄ (b) as their 5-HEAs PFB-TMS derivatives obtained by CAD of the corresponding parent ions $(M - PFB)^{-}$ on m/z 399 and m/z 403, respectively. The collision cell pressure was 3 mTorr and the collision energy 20 eV.

REFERENCES

- 1 M. Huber, S. Kästner, J. Schölmerich, W. Gerok and D. Keppler, Eur. J. Clin. Invest., 19 (1989) 53.
- 2 N. H. Maltby, G. W. Taylor, J. M. Ritter, K. Moore, R. W. Fuller and C. T. Dollery, *J. Allergy Clin. Immunol.*, 85 (1990) 3.
- 3 L. Örning, L. Kaijser and S. Hammarström, *Biochem. Biophys. Res. Commun., 130 (1985) 214.*
- 4 B. Samuelsson, Science (Washington, D.C.), 220 (1983) 568.
- 5 M. Huber, J. Miiller, I. Leier, G. Jedhtschky, H. A., Ball, K. P. Moore, G. W. Taylor, R. Williams and D. Keppler, *Eur. J. Biochem., 195 (1990) 309.*
- *6* A. P. Sampson, D. A. Spencer, C. P. Green, P. J. Piper and J. F. Price, Br. J. Clin. *Pharmacol., 30* (1990) 861.
- 7 J. Fauler, D. Tsikas, M. Holch, A. Seekamp, M. L. Nehrlich, J. Sturm and J. C. Frölich, *Clin. Sci.*, 80 (1991) 497.
- 8 L. Levine, R. A. Morgan, R. A. Lewis, K. F. Austen, D. A. Clark, A. Marfat and E. J. Corey, *Proc. Nutl. Acud. Sci. U.S.A., 78 (1981) 7692.*
- 9 E. C. Hayes, D. L. Lombardo, Y. Girard, A. Maycock, J. Rokach, A. S. Rosenthal, R. N. Young and H. J. Zweerink, J. *Immunol.,* 131 (1983) 429.
- 10 P. Pradelles, J. Grassi and J. Maclont, *Anal. Chem., 57 (1985) 1170.*
- 11 M. Balazy and R. C. Murphy, Anal. Chem., 58 (1986) 1098.
- 12 W. C. Picket and R. C. Murphy, Anal. Biochem., 111 (1981) 115.
- 13 J. Y. Westcott, K. L. Clay and R. C. Murphy, Biomed. Mass *Spectrom., 12 (1985) 714.*
- *14* H.-J. Leis, W. Welz and E. Malle, J. *Chromatogr., 526 (1990) 169.*
- 15 D. Tsikas, J. Fauler and J. C. Frölich, in preparation.